VLP Therapeutics, founded in Gaithersburg, United States, is a biopharmaceutical company dedicated to developing innovative vaccines and targeted antibody agents. Their core mission is to combat cancer and infectious diseases such as malaria, dengue fever, Zika virus-based diseases, and autoimmune disorders through next-generation therapeutic solutions. The company leverages advanced technologies like Surface Antigen Display and Interior Gene Delivery to create effective preventative and therapeutic vaccines.
Notable figures associated with VLP Therapeutics include its founders and an esteemed advisory board comprising experts in the field. The company has garnered attention for its significant achievements, including the development of a dengue vaccine that successfully induces antibodies and reduces replication. VLP Therapeutics' work has had a substantial impact on global health, positioning them as a key player in the fight against some of the world's most challenging diseases.
